查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1720007

医院获得性感染治疗市场，按药物类型、给药途径、感染类型、国家和地区划分：行业分析、市场规模、市场份额及 2025 年至 2032 年预测

Hospital Acquired Infections Therapeutic Market, By Drug Type, By Route of Administration, By Infection Type, By Country, and By Region: Industry Analysis, Market Size, Market Share, and Forecast from 2025 to 2032
出版日期: | 出版商: AnalystView Market Insights | 英文 396 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

医院获得性感染治疗市场规模预计在 2024 年达到 138.75 亿美元，2025 年至 2032 年期间的复合年增长率为 3.70%。

医院获得性感染治疗市场-市场动态

医疗保健支出上涨推动市场成长

预计医疗保健成本的上涨将推动医院感染控制市场的成长。医疗保健支出是指在特定时期内，通常在个人、社区、国家或全球范围内，用于医疗保健相关服务、产品和活动的总支出。随着医疗保健支出的增加，医院和医疗机构正准备分配更多资源用于采用先进的感染预防技术​​，其中包括先进的消毒系统、智慧监控设备等创新解决方案以及其他改善整体感染控制措施的技术。例如，2024 年 5 月，英国政府部门国家统计局报告称，2022 年至 2023 年期间，医疗保健总支出名义上增长了 5.6%，而 2022 年的增长率为 0.9%。因此，医疗保健支出的增加将推动未来医院获得性感染控制市场的成长。

医院获得性感染治疗市场—关键洞察

根据我们的研究分析师预测，2025 年至 2032 年间全球市场的复合年增长率将达到约 3.70%。

根据药品类型细分，抗菌药物类别收入最高。

根据感染类型细分，2024 年，血液感染细分市场占据主导地位。

按地区划分，2024 年欧洲的收入最高。

医院获得性感染治疗市场-細項分析：

全球离型膜市场分为四大类：药物类型、给药途径、感染类型、地理位置。

根据药物类型，市场分为四类：抗菌药物、抗真菌药物、抗病毒药物和其他药物类型。 2024 年，抗菌药物占据了 HAI 治疗市场的主导地位。这种主导地位是因为细菌是导致绝大多数 HAI 的原因。因此，医院获得性感染有很大一部分是用抗菌药物治疗的。此外，抗菌疗法是所有医院内感染的第一线治疗方法。所有感染革兰氏阳性和革兰氏阴性病原体的患者都必须接受抗生素治疗。应先根据多种耐多药细菌的危险因子来考虑经验性抗生素治疗。经验性抗生素疗法用于预防肾臟损伤、肾盂肾炎和血液感染等併发症。抗菌治疗最短可至7天，最长可至14-21天。

根据感染类型，市场分为五个部分：手术部位感染、泌尿道感染、血液感染、呼吸器相关性肺炎和其他医院感染。 2024 年，血液感染领域占据最大的市场份额。血流感染，也称为败血症或菌血症，是由细菌或其他病原体进入血液引起的严重感染。它们是由多种微生物引起的，包括细菌、病毒和真菌，并可能导致严重的併发症，如感染性休克、器官衰竭和死亡。血流感染是医院内发病和死亡的主要原因，尤其是重症病人。

医院获得性感染治疗市场—地理洞察

该市场在地理上分布广泛，涵盖欧洲、中东、北美、亚太地区、非洲和拉丁美洲。这些地区根据带来贸易的国家进一步划分。 2024 年，欧洲将主导 HAI 治疗市场，预计这一趋势将在整个研究期间持续下去。这种优势归因于欧洲国家医院获得性感染的高发性，以及该地区越来越多的新型医院获得性感染疗法的批准和推出。此外，由于葛兰素史克公司、罗氏公司、艾尔建公司和拜耳公司等主要公司在欧洲国家的存在，新型医院内感染治疗药物在欧洲国家的供应增加，预计将支持该地区的成长。

预计预测期内亚太地区的 HAI 治疗市场将大幅成长。这一增长是由于印度和中国等新兴经济体中慢性病盛行率上升，导致住院人数增加。例如，Globocan 报告称，2018 年中国诊断出约 4,285,033 例新癌症病例。因此，预计医院获得性感染和住院率的上升将推动对医院获得性感染治疗药物的需求并支持区域增长。

医院获得性感染治疗市场-竞争格局：

默克公司、雅培、罗氏公司、艾伯维和艾尔建等主要製药公司在医院获得性感染 (HAI) 治疗市场展开竞争，专注于开发创新抗生素和抗菌疗法。此外，新兴生物技术公司正在研究单株抗体和噬菌体疗法等利基治疗方法。作为改善药物开发和应对医院获得性感染日益增多的一种方式，成熟公司和新创公司之间的合作正变得越来越普遍。随着抗生素抗药性的蔓延，竞争日益激烈，凸显了医疗环境中对有效治疗方案和更好的病患治疗效果的需求。例如，2024 年 4 月，FDA 批准了巴塞利亚製药国际有限公司 (Basilea Pharmaceutica International Ltd.) 的新型血液感染治疗药物 Zevtera，标誌着该公司达到了一个重要的里程碑。此次批准对于 Basilea 来说是一项重大策略倡议，巩固了其在 HAI 治疗领域的市场领先地位。 Zevtera 的核准将拓宽严重感染的治疗选择，改善患者的治疗效果，并透过创新解决方案增强 Basilea 的市场地位。

最新动态：

2023 年 10 月，Spartan Medical Inc. 发起了一项新活动，以提高全美对手术部位感染 (SSI) 及其后果的认识。该策略旨在教育医疗保健专业人员和患者了解 SSI 的风险和预防的重要性，从而增加对先进感染控制措施和治疗解决方案的需求。这项活动强调了 Spartan Medical 致力于解决关键医疗保健挑战的决心，从而加强了该公司在感染控制市场的地位。

2022 年 4 月，辉瑞签署最终协议，收购 ReViral，这是一家专注于开发呼吸道合胞病毒 (RSV) 抗病毒疗法的临床阶段生物製药公司。此次收购将有助于辉瑞扩大在抗病毒治疗领域的影响力，并支持其开发呼吸道合胞病毒和其他呼吸道感染的新疗法。

2021 年 12 月，默克（在美国和加拿大以外地区称为 MSD）和 Ridgeback Biotherapeutics 宣布，他们的抗病毒药物莫努皮拉韦已获得美国食品药物管理局 (FDA) 的紧急使用授权 (EUA)，用于治疗 COVID-19。这是全球对抗新冠肺炎疫情努力向前迈出的重要一步，它继承了默克公司开发应对重大健康威胁和改善患者预后的创新药物的历史。

目录

第一章：医院获得性感染治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 院内获得性感染治疗市场（依药物类型）
    • 院内获得性感染治疗市场片段（依给药途径）
    • 院内获得性感染治疗市场片段（依感染类型）
    • 医院获得性感染治疗市场（按国家/地区）
    • 医院获得性感染治疗市场（按地区）
  • 竞争洞察

第三章：医院内获得性感染治疗关键市场趋势

  • 医院获得性感染治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 医院内感染治疗市场限制
    • 市场限制的影响分析
  • 医院获得性感染治疗市场机会
  • 医院获得性感染治疗市场未来趋势

第四章：医院内获得性感染治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：医院获得性感染治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • 新冠疫情后影响分析
    • 表现最佳的市场区隔
    • 边际成长细分市场
    • 最鬆散的细分市场
    • 边际损失部分

第六章：医院内获得性感染治疗市场格局

  • 2024年医院获得性感染治疗市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：医院获得性感染治疗市场－依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 抗菌药物
    • 抗真菌药物
    • 抗病毒药物
    • 其他药物类型

第 8 章：医院获得性感染治疗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 静脉注射（IV）
    • 外用
    • 口服
    • 吸入

第九章：医院获得性感染治疗市场－依感染类型

  • 概述
    • 按感染类型分類的细分份额分析
    • 手术部位感染
    • 泌尿道感染
    • 血流感染
    • 呼吸器相关性肺炎
    • 其他医院感染

第 10 章：医院获得性感染治疗市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美医院内感染治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依药品类型）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模及预测（按感染类型）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲医院获得性感染治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依药品类型）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（按感染类型）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区医院内感染治疗主要製造商
    • 亚太市场规模及预测（按国家/地区）
    • 亚太市场规模及预测（依药品类型）
    • 亚太地区市场规模及预测（依给药途径）
    • 亚太市场规模及预测（依感染类型）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲医院内感染治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依药品类型）
    • 拉丁美洲市场规模及预测（按给药途径）
    • 拉丁美洲市场规模及预测（按感染类型）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲医院获得性感染治疗主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（依药品类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按感染类型）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：关键供应商分析-医院获得性感染治疗产业

  • 竞争仪錶板
  • 公司简介
    • Merck & Co.
    • Abbott
    • F. Hoffmann-La Roche
    • AbbVie
    • Allergan Plc
    • Eugia Pharma
    • Bayer
    • DAIICHI SANKYO COMPANY
    • Glenmark Pharmaceuticals
    • GSK
    • Hikma Pharmaceuticals
    • Melinta Therapeutics
    • Pfizer
    • Sanofi
    • Viatris
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5006

REPORT HIGHLIGHT

Hospital Acquired Infections Therapeutic Market size was evaluated at USD 13,875 million in 2024, rising at a CAGR of 3.70% between 2025 and 2032.

Hospital-acquired infections are infections that develop during hospitalisation that were not present before admission. Hospital-acquired infection control refers to the prevention and control of hospital-acquired infections through various cleaning, sterilisation, and disinfection techniques. These infections can be caused by cross-contamination of equipment surfaces, patient skin, and healthcare staff. Infection control in hospitals is used to reduce or eliminate disease transmission.

Hospital Acquired Infections Therapeutic Market- Market Dynamics

Rising healthcare expenditures drive market Growth

Rising healthcare costs are expected to drive the growth of the hospital-acquired infection control market. Healthcare expenditures are the total amount spent on healthcare-related services, products, and activities over a given period, usually on an individual, community, national, or global scale. As healthcare spending rises, hospitals and healthcare facilities are preparing to allocate more resources to the adoption of advanced infection prevention technologies, which include innovative solutions such as advanced disinfection systems, smart monitoring devices, and other technologies that improve overall infection control measures. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to 0.9% in 2022. As a result, rising healthcare expenditure will drive future growth in the hospital-acquired infection control market.

Hospital Acquired Infections Therapeutic Market- Key Insights

According to our research analyst, the global market is expected to increase at a CAGR of approximately 3.70% between 2025 and 2032.

Based on Drug Type segmentation, the antibacterial drugs category had the highest income.

Based on Infection Type segmentation, In 2024, the bloodstream infections segment dominated the market.

According to region, Europe had the most revenue in 2024.

Hospital Acquired Infections Therapeutic Market- Segmentation Analysis:

The global release liner market is divided into four groups: Drug Type, Route of Administration, Infection Type, and geography.

The market is divided into four categories based on drug type: antibacterial drugs, antifungal drugs, antiviral drugs, and other drug types. Antibacterial drugs dominated the HAI therapeutics market in 2024. This dominance is because bacteria cause the vast majority of HAIs. As a result, a large proportion of HAIs are treated with antibacterial drugs. Furthermore, antibacterial therapy is the first line of treatment for all hospital-acquired infections. All patients infected with gram-positive and gram-negative pathogens must be treated with antibiotics. Empiric antibiotic therapy should be considered first based on a variety of risk factors for multidrug-resistant bacteria. Empiric antibiotic therapy is used to prevent complications like kidney damage, pyelonephritis, and bloodstream infections. Antibacterial therapy can be as short as 7 days or as long as 14-21 days.

Based on the type of infection, the market is divided into five segments: surgical site infections, urinary tract infections, bloodstream infections, ventilator-associated pneumonia, and other hospital infections. In 2024, the bloodstream infections segment held the largest market share. Bloodstream infections, also referred to as sepsis or bacteremia, are serious infections caused by bacteria or other pathogens entering the bloodstream. They are caused by a variety of microorganisms, including bacteria, viruses, and fungi, and can lead to serious complications like septic shock, organ failure, and death. Bloodstream infections are a major cause of morbidity and mortality in hospital settings, particularly among critically ill patients.

Hospital Acquired Infections Therapeutic Market- Geographical Insights

This market is geographically diversified across Europe, the Middle East, North America, Asia Pacific, and Africa, Latin America. The regions are further divided by the nations that bring commerce. In 2024, Europe dominated the market for HAI therapeutics, and this trend is expected to continue throughout the study period. This dominance is attributed to the high prevalence of HAIs in European countries, as well as the region's increasing approvals and launches of novel HAI therapeutics. Furthermore, the increased availability of novel hospital-acquired infection therapeutics in European countries due to the local presence of major players such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG is expected to support regional growth.

The HAIs therapeutics market in Asia Pacific is expected to grow significantly during the forecast period. This increase is attributed to the rising prevalence of chronic diseases in emerging economies like India and China, which has resulted in more hospitalisations. For example, Globocan reported that approximately 4,285,033 new cancer cases were diagnosed in China in 2018. Thus, the rising rate of HAIs and hospitalisations is expected to drive demand for HAI therapeutic drugs and support regional growth.

Hospital Acquired Infections Therapeutic Market- Competitive Landscape:

Major pharmaceutical companies such as Merck & Co., Abbott, F. Hoffmann-La Roche, AbbVie, and Allergan Plc compete in the Hospital Acquired Infections (HAIs) Therapeutic Market, with a focus on developing innovative antibiotics and antimicrobial therapies. Additionally, emerging biotech firms are investigating niche treatments such as monoclonal antibodies and bacteriophage therapy. Collaborations between established companies and startups are becoming more common as a way to improve drug development and address the rising prevalence of HAIs. As antibiotic resistance spreads, competition heats up, highlighting the need for effective treatment options and better patient outcomes in healthcare settings. For instance, in April 2024, Basilea Pharmaceutica International Ltd. reached a significant milestone when the FDA approved its new bloodstream infection treatment, Zevtera. This approval is a significant strategic move for Basilea, cementing its position as a market leader in HAI therapies. Zevtera's approval will broaden treatment options for severe infections, improving patient outcomes and strengthening Basilea's market presence through innovative solutions.

Recent Developments:

In October 2023, Spartan Medical Inc. launched a new campaign to increase awareness of surgical site infections (SSIs) and their consequences throughout the United States. This strategy aims to educate healthcare professionals and patients about the risks of SSIs and the importance of prevention, resulting in increased demand for advanced infection control measures and therapeutic solutions. The campaign strengthens Spartan Medical's position in the infection control market by emphasising the company's dedication to addressing critical healthcare challenges.

In April 2022, Pfizer signed a definitive agreement to acquire ReViral, a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory syncytial virus (RSV). The acquisition will help Pfizer expand its presence in the antiviral therapeutics field and support its efforts to develop new treatments for RSV and other respiratory infections.

In December 2021, Merck, also known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that their antiviral drug molnupiravir has been granted Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of COVID-19. This is a significant step forward in the global effort to combat the COVID-19 pandemic, building on Merck's history of developing innovative drugs that address major health threats and improve patient outcomes.

SCOPE OF THE REPORT

This report's scope includes the following important market segments:

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Merck & Co.
  • Abbott
  • F. Hoffmann-La Roche
  • AbbVie
  • Allergan Plc
  • Eugia Pharma
  • Bayer
  • DAIICHI SANKYO COMPANY
  • Glenmark Pharmaceuticals
  • GSK
  • Hikma Pharmaceuticals
  • Melinta Therapeutics
  • Pfizer
  • Sanofi
  • Viatris
  • Others

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antibacterial drugs
  • Antifungal drugs
  • Antiviral drugs
  • Other drug types

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Topical
  • Oral
  • Inhalation

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Surgical site infections
  • Urinary tract infections
  • Bloodstream infections
  • Ventilator-associated pneumonia
  • Other hospital infections

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hospital Acquired Infections Therapeutic Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hospital Acquired Infections Therapeutic Market Snippet by Drug Type
    • 2.1.2. Hospital Acquired Infections Therapeutic Market Snippet by Route of Administration
    • 2.1.3. Hospital Acquired Infections Therapeutic Market Snippet by Infection Type
    • 2.1.4. Hospital Acquired Infections Therapeutic Market Snippet by Country
    • 2.1.5. Hospital Acquired Infections Therapeutic Market Snippet by Region
  • 2.2. Competitive Insights

3. Hospital Acquired Infections Therapeutic Key Market Trends

  • 3.1. Hospital Acquired Infections Therapeutic Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hospital Acquired Infections Therapeutic Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hospital Acquired Infections Therapeutic Market Opportunities
  • 3.4. Hospital Acquired Infections Therapeutic Market Future Trends

4. Hospital Acquired Infections Therapeutic Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hospital Acquired Infections Therapeutic Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hospital Acquired Infections Therapeutic Market Landscape

  • 6.1. Hospital Acquired Infections Therapeutic Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hospital Acquired Infections Therapeutic Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Antibacterial drugs
    • 7.1.3. Antifungal drugs
    • 7.1.4. Antiviral drugs
    • 7.1.5. Other drug types

8. Hospital Acquired Infections Therapeutic Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Intravenous (IV)
    • 8.1.3. Topical
    • 8.1.4. Oral
    • 8.1.5. Inhalation

9. Hospital Acquired Infections Therapeutic Market - By Infection Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Infection Type, 2024 & 2032 (%)
    • 9.1.2. Surgical site infections
    • 9.1.3. Urinary tract infections
    • 9.1.4. Bloodstream infections
    • 9.1.5. Ventilator-associated pneumonia
    • 9.1.6. Other hospital infections

10. Hospital Acquired Infections Therapeutic Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Hospital Acquired Infections Therapeutic Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Hospital Acquired Infections Therapeutic Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co.
    • 11.2.2. Abbott
    • 11.2.3. F. Hoffmann-La Roche
    • 11.2.4. AbbVie
    • 11.2.5. Allergan Plc
    • 11.2.6. Eugia Pharma
    • 11.2.7. Bayer
    • 11.2.8. DAIICHI SANKYO COMPANY
    • 11.2.9. Glenmark Pharmaceuticals
    • 11.2.10. GSK
    • 11.2.11. Hikma Pharmaceuticals
    • 11.2.12. Melinta Therapeutics
    • 11.2.13. Pfizer
    • 11.2.14. Sanofi
    • 11.2.15. Viatris
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us